Comparative safety analysis of anti-interleukin-4/interleukin-13 inhibitors and Janus Kinase inhibitors in atopic dermatitis

To the Editor: Anti-interleukin (IL)-4/IL-13-inhibitors and oral Janus Kinase (JAK) inhibitors represent milestones in atopic dermatitis (AD) treatment. However, they are not devoid of potential side effects.1,2 Considering their rising utilization and limited head-to-head comparisons in real-world settings, we conducted a retrospective cohort analysis to compare the safety of anti-IL-4/IL-13 and JAK inhibitors for AD.